Literature DB >> 21720660

Acitretin in dermatology: a review.

Lauren K Dunn1, Laini R Gaar, Brad A Yentzer, Jenna L O'Neill, Steven R Feldman.   

Abstract

INTRODUCTION: Acitretin is a systemic retinoid drug used in the treatment of severe psoriasis. It has also been used for a spectrum of other difficult-to-treat dermatoses, including hyperkeratotic and inflammatory dermatoses and non-melanoma skin cancers. Here we review the available data regarding both FDA-approved and off-label uses of acitretin, clinically relevant adverse events, precautions and monitoring.
METHODS: A PubMed literature search was conducted utilizing the search term "acitretin," which yielded 714 hits. Results were further limited to English language clinical trials in human subjects. Of 78 articles evaluated for relevance, 60 were included for review.
RESULTS: Acitretin is effective as monotherapy and in multidrug therapeutic regimens for the treatment of psoriasis and other hyperkeratotic and inflammatory disorders, as well as for malignancy chemoprevention. Its use is limited by its teratogenic potential and other adverse effects, including mucocutaneous effects and hepatotoxicity. Potential adverse effects may be reduced or avoided by using lower doses of acitretin or in combination with other therapies. LIMITATIONS: The reviewed studies include many small trials and case reports of the use of acitretin for psoriasis. Studies of acitretin therapy for the treatment of other cutaneous disorders are limited.
CONCLUSION: Acitretin is a beneficial treatment for psoriasis, and should be considered when not contraindicated. Particularly when used in combination with ultraviolet (UV) phototherapy, is a safe and cost effective therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720660

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  13 in total

1.  American academy of dermatology, summer academy meeting.

Authors:  Takaharu Kato; Peter Sonnenreich
Journal:  P T       Date:  2011-11

Review 2.  A Painful Periungual Red Spot in a Patient with Onychodystrophy.

Authors:  Ahu Yorulmaz; Basak Yalcin
Journal:  Skin Appendage Disord       Date:  2017-02-16

Review 3.  Cancer therapies in HIV cure research.

Authors:  Thomas A Rasmussen; Jenny L Anderson; Fiona Wightman; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

4.  Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models.

Authors:  Juliana Bragazzi Cunha; Jared S Elenbaas; Dhiman Maitra; Ning Kuo; Rodrigo Azuero-Dajud; Allison C Ferguson; Megan S Griffin; Stephen I Lentz; Jordan A Shavit; M Bishr Omary
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

Review 5.  Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?

Authors:  Alessandro Mantovani; Paolo Gisondi; Amedeo Lonardo; Giovanni Targher
Journal:  Int J Mol Sci       Date:  2016-02-05       Impact factor: 5.923

6.  Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation.

Authors:  M K Magnusson; S F Brynjólfsson; A Dige; H Uronen-Hansson; L G Börjesson; J L Bengtsson; S Gudjonsson; L Öhman; J Agnholt; H Sjövall; W W Agace; M J Wick
Journal:  Mucosal Immunol       Date:  2015-06-17       Impact factor: 7.313

7.  Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study.

Authors:  Irhan Ibrahim Abu Hashim; Noha Fawzy Abo El-Magd; Ahmed Ramadan El-Sheakh; Mohammed Fawzy Hamed; Abd El-Gawad Helmy Abd El-Gawad
Journal:  Int J Nanomedicine       Date:  2018-02-20

8.  Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study.

Authors:  Christian Kromer; Dagmar Wilsmann-Theis; Sascha Gerdes; Sandra Philipp; Marthe-Lisa Schaarschmidt; Astrid Schmieder; Mohammed Dakna; Tobias Arnold; Wiebke Katharina Peitsch; Rotraut Mössner
Journal:  J Dtsch Dermatol Ges       Date:  2019-04-17       Impact factor: 5.584

9.  [Appropriate off-label prescription in practice].

Authors:  M Augustin
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

10.  A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.

Authors:  Joo-Heung Lee; Jai-Il Youn; Tae-Yoon Kim; Jee-Ho Choi; Chul-Jong Park; Yong-Beom Choe; Hae-Jun Song; Nack-In Kim; Kwang-Joong Kim; Jeung-Hoon Lee; Hyun-Jeong Yoo
Journal:  BMC Dermatol       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.